Spyre Therapeutics, Inc. — Form 4
Filed August 10, 2026 · analyzed by the Insider Agent
4
▼ Likely negative
significance 54/100
What the filing says
Director Albers Jeffrey W. (SYRE) sold 28K shares (~$2.4M) on the open market (38% of holdings). Large sale — ~38% of holdings.
Why this rating
Large sale — ~38% of holdings.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.